CurrentBlue Cross Blue Shield - MassachusettsPolicy 009

Elzonris (tagraxofusp-erzs) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Prior Authorization

Requirements and prior authorization process for Elzonris (tagraxofusp-erzs) when used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) for BCBS Massachusetts members; describes documentation, submission channel, and site-of-care expectations affecting providers requesting coverage.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyElzonris (tagraxofusp-erzs) for BPDCN prior authorization

Policy CodePolicy 009

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit prior authorization via Authorization Manager using the Elzonris (928) prior authorization request form and include clinical documentation supporting medical necessity.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1required inpatient initial cycle

24hminimum monitoring (initial)

928prior auth form ID

Auth Managersubmission channel

Coverage Criteria for Elzonris (tagraxofusp-erzs)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial therapy coverage conditions

Covered when ALL of the following are met

Documented diagnosis: Confirmed diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) is provided.

Clinical background and diagnosis must be submitted.

Clinical documentation: Current laboratory results and ECOG performance score are submitted to support medical necessity.

If the patient does not meet all criteria, submit a letter of medical necessity requesting individual consideration.

Site-of-care requirement: Initial treatment cycle administered in an inpatient setting with monitoring for at least 24 hours after the last infusion.>= 24 hours

Subsequent cycles may be outpatient but require additional prior authorization.

The policy requires submission of clinical documentation that supports medical necessity for Elzonris (tagraxofusp-erzs) when used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). While the form does not enumerate explicit exclusions, lack of supporting documentation or failure to meet the medical necessity criteria described by the payer can preclude coverage. If the patient does not meet all listed criteria, providers should include a letter of medical necessity requesting an individual clinical exception.

Requests that do not meet the stated medical necessity criteria are not automatically supported; providers must pursue individual review by submitting a letter of medical necessity with the authorization request asking for Clinical Exception (Individual Consideration). All submissions should include the clinical documentation described by the payer to allow review.

Regimen	Coverage status	Notes
Elzonris (tagraxofusp-erzs) — initial treatment cycle administered inpatient with post-infusion monitoring	Covered	>= 24 hours of monitoring after the last infusion required for initial cycle; subsequent cycles may be given outpatient but require additional prior authorization
Elzonris (tagraxofusp-erzs) — subsequent treatment cycles administered outpatient	Covered	Outpatient administration of subsequent cycles requires additional prior authorization

Provider Submission and Documentation Requirements

Prior Authorization

Prior authorization submission — Authorization Manager primary channel

Use Authorization Manager as the primary channel to submit prior authorization requests for Elzonris (form 928). Authorization Manager is available 24/7 to submit requests, upload clinical documentation, check case status, and view/print decision letters. For out-of-network providers, continue to fax requests to 888-973-0726.

Enter the facility's NPI or provider ID for the service location.
Enter the servicing provider's NPI or provider ID (the clinician performing the service), not the billing group.
Complete the Prior Authorization Request Form for Elzonris (928) in Authorization Manager.

Note

Site-of-care and monitoring requirement — initial cycle inpatient with 24-hour post-infusion monitoring; subsequent cycles outpatient per policy

Initial cycle must be administered in an inpatient setting with monitoring for at least 24 hours after the last infusion. Subsequent cycles may be administered in an appropriate outpatient setting; additional prior authorization is required for those subsequent cycles.

Documentation Required

Required clinical documentation — diagnosis confirmation, labs, ECOG, clinical notes to support medical necessity

Submit clinical documentation that supports the medical necessity criteria for Elzonris (tagraxofusp-erzs) for treatment of BPDCN. If the patient does not meet all listed criteria, submit a letter of medical necessity requesting a Clinical Exception (Individual Consideration) explaining why an exception is justified.

Confirmed diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Current laboratory results relevant to therapy.
ECOG performance status.
Relevant clinical background and history.
Clinical notes that document disease status, prior therapies, and rationale for Elzonris.
Any additional supporting information (imaging, pathology reports, molecular testing) as applicable.

Denial Risk

Insufficient documentation or unmet criteria — denial risk if documentation not provided or criteria unmet

If supporting clinical documentation is not provided or the patient does not meet the medical necessity criteria, the request may be denied. To avoid denial, ensure all required documentation is uploaded with the prior authorization request or include a letter of medical necessity if requesting an exception.

Risk of denial when documentation is incomplete or criteria are unmet.
Submit a letter of medical necessity for requests that do not strictly meet policy criteria to request Individual Consideration.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyElzonris (tagraxofusp-erzs) for BPDCN prior authorization

Policy CodePolicy 009

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit prior authorization via Authorization Manager using the Elzonris (928) prior authorization request form and include clinical documentation supporting medical necessity.

SourceLink

On This Page

OpenPayer

Elzonris (tagraxofusp-erzs) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Prior Authorization

Coverage Criteria for Elzonris (tagraxofusp-erzs)

Form and Coding References

Provider Submission and Documentation Requirements

Line of Therapy Specifications

Definitions and Performance Status

Background